You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 4 | BMC Health Services Research

Figure 4

From: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

Figure 4

Incremental cost-effectiveness ratio (ICER) for different scenarios and ages; indirect costs are included (loss of working hours, only relevant for vaccination at 60 years of age). The base case (dark grey) is including a lower QALY loss in the first 6 months of HZ among vaccinees, in the 'without additional effect' (light grey) this is not included. Error bars represent 95% confidence intervals and under the bars the relevant cost-effectiveness ratios are shown.

Back to article page